Everything about Curcumenol
Risdiplam is the only orally administered drug authorised to the treatment of SMA. It had been FDA accredited in 2020 for use in people two months of age and older, and it capabilities being an SMN2 gene splicing modifier leading to increased amounts of SMN protein. Oral administration is a major advantage of this drug as it can impact systemic tis